Enzychem Lifesciences (XKRX:183490) Debt-to-Equity : 0.03 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Debt-to-Equity?

Enzychem Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,545 Mil. Enzychem Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,534 Mil. Enzychem Lifesciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩192,447 Mil. Enzychem Lifesciences's debt to equity for the quarter that ended in Mar. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enzychem Lifesciences's Debt-to-Equity or its related term are showing as below:

XKRX:183490' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.09 Max: 0.7
Current: 0.03

During the past 10 years, the highest Debt-to-Equity Ratio of Enzychem Lifesciences was 0.70. The lowest was 0.03. And the median was 0.09.

XKRX:183490's Debt-to-Equity is ranked better than
89.03% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs XKRX:183490: 0.03

Enzychem Lifesciences Debt-to-Equity Historical Data

The historical data trend for Enzychem Lifesciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Debt-to-Equity Chart

Enzychem Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.59

0.70

0.19

0.03

Enzychem Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.03	0.03	0.03	0.03

Competitive Comparison of Enzychem Lifesciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzychem Lifesciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's Debt-to-Equity falls into.

Enzychem Lifesciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enzychem Lifesciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4047.506	+	1609.453)	/	193515.937
	=	0.03

Enzychem Lifesciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3544.939	+	1534.101)	/	192446.79
	=	0.03

Enzychem Lifesciences (XKRX:183490) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Enzychem Lifesciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzychem Lifesciences (XKRX:183490) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280

Website

http://www.enzychem.com

Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences (XKRX:183490) Headlines

No Headlines